Zobrazeno 1 - 10
of 142
pro vyhledávání: '"Philip C, Hoffman"'
Autor:
Stanley I. Gutiontov, William Tyler Turchan, Liam F. Spurr, Sherin J. Rouhani, Carolina Soto Chervin, George Steinhardt, Angela M. Lager, Pankhuri Wanjari, Renuka Malik, Philip P. Connell, Steven J. Chmura, Aditya Juloori, Philip C. Hoffman, Mark K. Ferguson, Jessica S. Donington, Jyoti D. Patel, Everett E. Vokes, Ralph R. Weichselbaum, Christine M. Bestvina, Jeremy P. Segal, Sean P. Pitroda
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Abstract Immune checkpoint blockade (ICB) improves outcomes in non-small cell lung cancer (NSCLC) though most patients progress. There are limited data regarding molecular predictors of progression. In particular, there is controversy regarding the r
Externí odkaz:
https://doaj.org/article/82195ffa5c7b45b097938796d4698839
Autor:
Misha C. Tran, Garth W. Strohbehn, Theodore G. Karrison, Sherin J. Rouhani, Jeremy P. Segal, Ardaman Shergill, Philip C. Hoffman, Jyoti D. Patel, Marina C. Garassino, Everett E. Vokes, Christine M. Bestvina
Publikováno v:
Clinical Lung Cancer. 24:e117-e121
Autor:
Olufunmilayo I. Olopade, Vassily V. Trubetskoy, Rita Nanda, Jenny C. Chang, Douglas E. Merkel, E. Claire Dees, Minetta C. Liu, Nancy J. Cox, M. Eileen Dolan, R. Stephanie Huang, Antonio C. Wolff, Olwen Hahn, Andres Forero, Julianne P. Hall, Phuong Khanh Morrow, Vandana G. Abramson, Gini F. Fleming, Peter H. O'Donnell, Gary L. Rosner, James N. Ingle, Jeffrey Peppercorn, Aritro Nath, Philip C. Hoffman, Mark J. Ratain, Hope S. Rugo, Catherine Van Poznak, Ashley Nurhussein-Patterson, Dezheng Huo, Anna Maria Storniolo
Publikováno v:
Breast Cancer Research and Treatment. 181:623-633
Capecitabine is important in breast cancer treatment but causes diarrhea and hand-foot syndrome (HFS), affecting adherence and quality of life. We sought to identify pharmacogenomic predictors of capecitabine toxicity using a novel monitoring tool. P
Autor:
Mark A. Pietz, James R. Stout, Timothy D. White, Lu Yu, Joseph R. Martinelli, Charles A. Alt, Laura A. McKee, Paul K. Milenbaugh, Nessa Mullane, Moussa Boukerche, Alison Campbell Brewer, Philip C. Hoffman, Kobierski Michael Edward
Publikováno v:
Organometallic Chemistry in Industry
Autor:
Mark K. Ferguson, William Tyler Turchan, Sean P. Pitroda, Jessica S. Donington, Jyoti D. Patel, Renuka Malik, Sherin J. Rouhani, Steven J. Chmura, Christine M. Bestvina, Philip C. Hoffman, Angela M. Lager, Philip P. Connell, Carolina Soto Chervin, Aditya Juloori, George Steinhardt, Ralph R. Weichselbaum, Everett E. Vokes, Pankhuri Wanjari, Stanley I. Gutiontov, Jeremy P. Segal, Liam F. Spurr
Publikováno v:
Scientific Reports
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Immune checkpoint blockade (ICB) improves outcomes in non-small cell lung cancer (NSCLC) though most patients progress. There are limited data regarding molecular predictors of progression. In particular, there is controversy regarding the role of CD
Autor:
Michael J. Jelinek, Christine M. Bestvina, Septimiu Murgu, Hania A. Al-Hallaq, J.M. Melotek, Aditya Juloori, J. Partouche, Theodore Karrison, Sean P. Pitroda, Everett E. Vokes, Philip C. Hoffman, Ralph R. Weichselbaum, K.B. Pointer, Jyoti D. Patel, Steven J. Chmura
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 17(1)
Previous studies have evaluated stereotactic body radiotherapy (SBRT) in oligometastatic patients with NSCLC, including multimodality treatment with anti-programmed cell death protein-1 monotherapy. Questions remain regarding the timing of SBRT and i
Autor:
Roy S. Herbst, Primo N. Lara, Jeffrey D. Bradley, Philip C. Hoffman, Vassiliki A. Papadimitrakopoulou, Alfred J. Newman, Jieling Miao, Mary W. Redman, Karen Kelly, Marvin J. Feldman, Hossein Borghaei, Philip C. Mack, Katherine Minichiello, David R. Gandara, Charu Aggarwal
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, vol 14, iss 10
Background S1400D is a biomarker-driven therapeutic substudy of Lung-MAP evaluating the fibroblast growth factor (FGF) receptor (FGFR) inhibitor AZD4547 in patients with FGF pathway-activated squamous cell. This is the first phase II trial to evaluat
Autor:
Alison Campbell Brewer, David C. Robbins, Joseph R. Martinelli, Nessa Mullane, Philip C. Hoffman, Kobierski Michael Edward
Publikováno v:
Organic Process Research & Development. 23:1484-1498
Despite the benefits of high atom economy and low cost, aerobic oxidations have found limited use in the synthesis of active pharmaceutical ingredients (APIs) because of safety concerns and poor se...
Autor:
Sean P. Pitroda, Jyoti D. Patel, J. Segal, C. Soto Chervin, Sherin J. Rouhani, Philip C. Hoffman, Jessica S. Donington, Stanley I. Gutiontov, Christine M. Bestvina, Mark K. Ferguson, Steven J. Chmura, William Tyler Turchan, R. Malik, Ralph R. Weichselbaum, Everett E. Vokes, P.P. Connell, Aditya Juloori
Publikováno v:
Journal of Thoracic Oncology. 16:S341-S342
Autor:
Everett E. Vokes, Sherin J. Rouhani, Jeremy P. Segal, M. Tran, Garth W. Strohbehn, Philip C. Hoffman, Jyoti D. Patel, A. Shergill, Christine M. Bestvina
Publikováno v:
Journal of Thoracic Oncology. 16:S1032